CONTRACEPTION WITH DROSPIRENONE: EFFECT ON THE BODY WEIGHT AND SOME LIPID METABOLISM INDICATORS
https://doi.org/10.21518/2079-701X-2016-12-95-97
Abstract
The combined oral contraceptive containing 20 μg of ethinylestradiol and 3 μg of drospirenone is an effective contraception method with the optimum shortened hormone-free interval and good tolerance predetermined by the positive effect on the body weight, lipid metabolism, general state and symptoms related to liquid retention and hyperandrogenism. The data obtained in in vitro and in vivo studies about the role of drospirenone in blocking of adipocyte differentiation and triglyceride accumulation as well as about regulation of the white fat remodeling justify possible effects of this drug on prevention of negative metabolic consequences of the adipocyte dysfunction. Results of clinical studies are indicative of the body weight reduction and positive effect on the lipid profile without statistically significant effect on insulin sensitivity, which leads to high degree of the women satisfaction with this type of contraception.
About the Author
A. A. Smetnik
Kulakov Scientific Center of Obstetrics, Gynecology and Perinatology, Moscow
Russian Federation
Russian Federation
PhD in medicine
References
1. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003; 349: 1443.
2. Cremer M, Phan-Weston S, Jacobs A. Recent innovations in oral contraception. Semin Reprod Med. 2010; 28(2): 140-6.
3. Sober SP, Schreiber CA. Controversies in family planning: are all oral contraceptive formulations created equal? Contraception. 2011; 83: 394.
4. Foidart JM. Added benefits of drospirenone for compliance. Climacteric. 2005;8(3):28-34.
5. Bachmann G, Sulak PJ, Sampson-Landers C et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191.
6. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115.
7. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc). 2008;44(2):133-45.
8. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152(1):113-25.
9. Armani A, Cinti F, Marzolla V et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014 Aug;28(8):3745-57.
10. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124.
11. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care. 2000;5(3):25-33.
12. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;(1):CD003987.
13. Басова О.Н., Волков В.Г. Опыт применения комбинированного орального контрацептива, содержащего дроспиренон. Материалы Х юбилейного Всероссийского научного форума «Мать и дитя». 2009; с. 259-60./Basova O.N., Volkov V.G. Experience of application of combined oral contraceptive containing drospirenone. Materials of X Jubilee All-Russian Scientific Forum Mother and Child. 2009; p. 259-60.
14. Кузнецова И.В., Набиева П.А. Преимущества использования комбинированного орального контрацептива с дроспиреноном в режиме 24+4 у подростков с избыточной массой тела. Гинекология. 2014;16(1):49-53./Kuznetsova I.V., Nabieva P.A. Advantages of use of the combined oral contraceptive with drospirenone in the regime 24+4 in teenagers with the excessive bodyweight. Gynekologia. 2014; 16 (1): 49-53.
15. Cagnacci A, Piacenti I, Zanin R et al. Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women. Eur J Obstet Gynecol Reprod Biol. 2014;178:48-50.
16. Aydin K, Cinar N, Aksoy DY et al. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013;87(3):358-62.
17. Di Carlo C, Tommaselli GA, De Rosa N et al. Plasma leptin and adiponectin levels in hormone replacement therapy and contraception: effects of different progestogens. Fertil Steril. 2011;96(1):214-9.
18. Bitzer J, Paoletti AM. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin Drug Investig. 2009;29(2):73-8.
19. Rezk M, Sayyed T, Ellakwa H et el. Metabolic changes in overweight and obese women above 35 years using Ethinylestradiol/drosperinone combined contraceptive pills: a 3-year case-control study. Gynecol Endocrinol. 2016:1-4. [Epub ahead of print].
Review
For citations:
Smetnik AA. CONTRACEPTION WITH DROSPIRENONE: EFFECT ON THE BODY WEIGHT AND SOME LIPID METABOLISM INDICATORS. Meditsinskiy sovet = Medical Council. 2016;(12):95-97. (In Russ.) https://doi.org/10.21518/2079-701X-2016-12-95-97
Views:
3474
Email this article 